[go: up one dir, main page]

MX2016001186A - Diagnostico y terapia de cancer que implica celulas madre cancerosas. - Google Patents

Diagnostico y terapia de cancer que implica celulas madre cancerosas.

Info

Publication number
MX2016001186A
MX2016001186A MX2016001186A MX2016001186A MX2016001186A MX 2016001186 A MX2016001186 A MX 2016001186A MX 2016001186 A MX2016001186 A MX 2016001186A MX 2016001186 A MX2016001186 A MX 2016001186A MX 2016001186 A MX2016001186 A MX 2016001186A
Authority
MX
Mexico
Prior art keywords
cancerosas
implies
therapy
cancer diagnosis
stem cells
Prior art date
Application number
MX2016001186A
Other languages
English (en)
Other versions
MX385872B (es
Inventor
Ugur Sahin
Özlem Türeci
Maria Kreuzberg
Korden Walter
Stefan Jacobs
Meike Wagner
Sabine Häcker
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX2016001186A publication Critical patent/MX2016001186A/es
Publication of MX385872B publication Critical patent/MX385872B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona métodos para diagnóstico o tratamiento de enfermedades cancerosas que implican células madre cancerosas que comprenden CLDN6 objetivo. En particular, la presente invención proporciona un método para determinar células madre cancerosas que comprenden detectar las células que expresan CLDN6. Adicionalmente, la presente invención proporciona un método para tratar o prevenir cáncer que comprende inhibir y/o eliminar células madre cancerosas al administrar un anticuerpo que tiene la capacidad de ligarse a CLDN6 a un paciente con cáncer.
MX2016001186A 2013-07-31 2014-07-30 Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer MX385872B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/002272 WO2015014376A1 (en) 2013-07-31 2013-07-31 Diagnosis and therapy of cancer involving cancer stem cells
PCT/EP2014/066330 WO2015014870A1 (en) 2013-07-31 2014-07-30 Diagnosis and therapy of cancer involving cancer stem cells

Publications (2)

Publication Number Publication Date
MX2016001186A true MX2016001186A (es) 2016-07-15
MX385872B MX385872B (es) 2025-03-18

Family

ID=48914215

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016001186A MX385872B (es) 2013-07-31 2014-07-30 Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
MX2021010672A MX2021010672A (es) 2013-07-31 2016-01-27 Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010672A MX2021010672A (es) 2013-07-31 2016-01-27 Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.

Country Status (19)

Country Link
US (3) US10604568B2 (es)
JP (5) JP2016533738A (es)
KR (4) KR102483410B1 (es)
CN (3) CN113252898A (es)
AR (1) AR097178A1 (es)
AU (3) AU2014298505B2 (es)
BR (1) BR112016002000A2 (es)
CA (1) CA2919570A1 (es)
DK (1) DK3027208T3 (es)
ES (2) ES2807181T3 (es)
HU (1) HUE050622T2 (es)
IL (4) IL308523B2 (es)
MX (2) MX385872B (es)
NZ (1) NZ716473A (es)
PT (1) PT3027208T (es)
RU (2) RU2020123616A (es)
SG (2) SG10201800834RA (es)
UA (1) UA123428C2 (es)
WO (2) WO2015014376A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2398902T3 (da) 2009-02-20 2023-12-04 Astellas Pharma Inc Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341147B (es) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
US10591154B2 (en) * 2015-03-31 2020-03-17 Mitsubishi Hitachi Power Systems, Ltd. Combustion burner and boiler
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2017008046A1 (en) * 2015-07-08 2017-01-12 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
WO2018232349A1 (en) * 2017-06-15 2018-12-20 Development Center For Biotechnology Antibody-drug conjugates containing anti-globo h antibodies and uses thereof
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
WO2019053012A1 (en) 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS
JP7599332B2 (ja) * 2017-09-18 2024-12-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６抗体及びがんを治療するための方法
JP7273716B2 (ja) 2017-09-29 2023-05-15 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
US20210317453A1 (en) * 2018-08-13 2021-10-14 Cancerstem Tech Inc. Cancer stem cell marker and cancer stem cell targeting drug
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
ES3017207T3 (en) 2019-03-20 2025-05-12 Univ California Claudin-6 antibodies and drug conjugates
PH12021552960A1 (en) * 2019-07-10 2022-07-25 Chugai Pharmaceutical Co Ltd Claudin-6 binding molecules and uses thereof
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
CN113832226B (zh) * 2020-06-24 2023-06-30 广州医科大学附属第五医院 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途
WO2022178218A1 (en) 2021-02-19 2022-08-25 Mevion Medical Systems, Inc. Gantry for a particle therapy system
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
EP1127119A1 (en) 1998-11-03 2001-08-29 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
AU3124000A (en) 1998-12-17 2000-07-03 Human Genome Sciences, Inc. 47 human secreted proteins
AU3479700A (en) 1999-02-22 2000-09-14 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
ES2287020T3 (es) 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
WO2001053312A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
JP2004514420A (ja) 2000-07-20 2004-05-20 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7351802B2 (en) 2000-07-25 2008-04-01 Genentech, Inc. PRO19672 antibodies
CA2422155A1 (en) 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100788092B1 (ko) 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
KR20040101502A (ko) 2002-04-16 2004-12-02 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT1558648E (pt) 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
CA2503043A1 (en) 2002-10-18 2004-07-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
KR20060035608A (ko) 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
JP2007516693A (ja) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
NZ576751A (en) * 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
EP2138576A4 (en) 2007-03-16 2011-02-23 Kyowa Hakko Kirin Co Ltd ANTI-CLAUDIN-4 ANTIBODY
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CA2711557A1 (en) * 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
JP2011515497A (ja) * 2008-03-26 2011-05-19 セレラント セラピューティクス インコーポレイテッド 骨髄性血液学的増殖性疾患と関連する免疫グロブリンおよび／またはＴｏｌｌ様受容体タンパク質ならびにその使用
WO2009126926A2 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
EP2352764B1 (en) 2008-10-14 2018-03-28 Ablynx N.V. AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
DK2398902T3 (da) 2009-02-20 2023-12-04 Astellas Pharma Inc Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
SG10202110692WA (en) 2009-11-11 2021-12-30 Ganymed Pharmaceuticals Gmbh Antibodies specific for claudin 6 (cldn6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
JP2011213612A (ja) * 2010-03-31 2011-10-27 Kyowa Hakko Kirin Co Ltd 癌幹細胞及び／または癌前駆細胞の減少剤
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341147B (es) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
EP2749641B1 (en) * 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
KR101242726B1 (ko) 2012-01-26 2013-03-13 한국과학기술원 종양줄기세포 특성 암의 진단 및 치료제
CN104703999A (zh) 2012-07-19 2015-06-10 安姆根有限公司 人btnl3蛋白、核酸和抗体及其用途
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
KR102643443B1 (ko) * 2012-11-13 2024-03-06 비온테크 에스이 클라우딘 발현 암 질환의 치료제
RS62565B1 (sr) * 2013-03-14 2021-12-31 Translate Bio Inc Metode i kompozicije za isporuku antitela kodiranih od strane irnk
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells

Also Published As

Publication number Publication date
IL308523B1 (en) 2025-01-01
KR20240060738A (ko) 2024-05-08
MX385872B (es) 2025-03-18
KR20160034417A (ko) 2016-03-29
ES3041948T3 (en) 2025-11-17
AU2014298505A1 (en) 2016-02-18
KR102483410B1 (ko) 2022-12-30
KR102308813B1 (ko) 2021-10-06
HUE050622T2 (hu) 2021-01-28
IL243408A0 (en) 2016-03-31
IL293880B2 (en) 2024-07-01
AU2022206711B2 (en) 2025-09-04
US20240059772A1 (en) 2024-02-22
WO2015014376A1 (en) 2015-02-05
UA123428C2 (uk) 2021-04-07
AU2020201331B2 (en) 2022-04-21
CN113406327B (zh) 2023-10-31
AR097178A1 (es) 2016-02-24
US20160159901A1 (en) 2016-06-09
RU2016107005A3 (es) 2018-03-30
US10604568B2 (en) 2020-03-31
JP7611196B2 (ja) 2025-01-09
WO2015014870A1 (en) 2015-02-05
IL293880A (en) 2022-08-01
IL243408B (en) 2022-07-01
JP2019110907A (ja) 2019-07-11
JP6865778B2 (ja) 2021-04-28
MX2021010672A (es) 2021-12-10
JP2016533738A (ja) 2016-11-04
SG10201800834RA (en) 2018-03-28
CN105407922B (zh) 2021-06-25
NZ716473A (en) 2022-02-25
KR102663127B1 (ko) 2024-05-07
AU2022206711A1 (en) 2022-08-11
CN113252898A (zh) 2021-08-13
IL293880B1 (en) 2024-03-01
SG11201600722PA (en) 2016-02-26
US20200385460A1 (en) 2020-12-10
CN113406327A (zh) 2021-09-17
DK3027208T3 (da) 2020-07-27
RU2020123616A (ru) 2020-09-10
IL308523A (en) 2024-01-01
BR112016002000A2 (pt) 2017-08-29
RU2749867C2 (ru) 2021-06-17
JP7136822B2 (ja) 2022-09-13
US11795218B2 (en) 2023-10-24
RU2016107005A (ru) 2017-09-04
CN105407922A (zh) 2016-03-16
ES2807181T3 (es) 2021-02-22
AU2020201331A1 (en) 2020-03-12
JP2023009039A (ja) 2023-01-19
JP2025011178A (ja) 2025-01-23
PT3027208T (pt) 2020-07-20
KR20210120142A (ko) 2021-10-06
CA2919570A1 (en) 2015-02-05
AU2014298505B2 (en) 2019-12-19
KR20230007548A (ko) 2023-01-12
JP2020101558A (ja) 2020-07-02
IL308523B2 (en) 2025-05-01
KR102867808B1 (ko) 2025-10-13
IL310824A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
MX2016001186A (es) Diagnostico y terapia de cancer que implica celulas madre cancerosas.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MY193705A (en) Fgfr/pd-1 combination therapy for the treatment of cancer
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
ECSP12012309A (es) Anticuerpos hacia gdf8 humano
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
EA201790398A1 (ru) Способы лечения заболевания печени
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
IN2015DN00450A (es)
AR101740A1 (es) Terapia de combinación y composiciones
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
MX2017009694A (es) Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l).
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.